Alle Storys
Folgen
Keine Story von Deutsche Effecten- und Wechsel-Beteiligungsges. AG mehr verpassen.

Deutsche Effecten- und Wechsel-Beteiligungsges. AG

EANS-News: DEWB Investment Holding NOXXON Announces Initiation of First Clinical Trial with a Spiegelmer®

Berlin/Jena, Germany, 8 June 2009 (euro adhoc) -

  Corporate news transmitted by euro adhoc. The issuer/originator is solely
  responsible for the content of this announcement.
investments
NOXXON Pharma AG
(NOXXON), an investment holding of Deutsche Effecten- und 
Wechsel-Beteiligungsgesellschaft AG (DEWB), announced today the 
successful initial dosing of healthy volunteers with Spiegelmer® 
NOX-E36 in the company´s first-in-human clinical trial. The Phase I 
program is currently underway in the United Kingdom following review 
and approval of the Clinical Trial Application by the Medicines and 
Health product Regulatory Authority (MHRA). The study will evaluate 
the tolerability, safety and pharmacokinetics in up to 72 individuals
following intravenous and subcutaneous administration of 
anti-inflammatory Spiegelmer® NOX-E36. The results obtained in the 
Phase I trial will guide the Phase II program to be conducted in 
patients suffering from nephropathy.
"With the initiation of this Phase I study, Spiegelmers® have reached
the next level of maturity", commented Dr. Frank Morich, Chief 
Executive Officer of NOXXON. "This event marks NOXXON´s transition to
a clinical-stage company and represents a major milestone in our 
continued effort to develop a pipeline of a novel and innovative 
class of pharmaceuticals to address major medical needs."
"With its innovative Spiegelmer® technology NOXXON is one of the most
promising biotechnology companies", commented Bertram Köhler, Member 
of the Management Board of DEWB and deputy chairman of NOXXON´s 
supervisory board. "Entering the clinical trials and being first in 
man with a Spiegelmer® is a tremendous success in the company´s 
development and proofs the chosen strategy in 2006". Besides DEWB, 
which holds the largest share in NOXXON, the group of investors 
includes leading European venture capitalists in biotechnology - TVM 
Capital, Sofinnova Partners and Edmond de Rothschild Investment 
Partners.
Spiegelmers® (L-aptamers) are chemical entities based on synthetic 
mirror-image oligonucleotides.  Thanks to their unique mirror image 
configuration Spiegelmers® are not metabolized and do not hybridize 
with native DNA or RNA. Spiegelmers® also do not activate the innate 
immune response via Toll-like receptors and have shown an 
exceptionally favorable immunogenicity profile in pre-clinical 
testing.
NOXXON´s lead compound NOX-E36 is a new therapeutic modality that 
specifically targets the pro-inflammatory chemokine Monocyte 
Chemotactic Protein 1 (MCP-1, also known as CCL2). Previously 
completed experiments in various animal models of kidney disease 
demonstrate that treatment with Spiegelmer® MCP-1 antagonists 
significantly delays the decline in kidney function as well as 
disease progression. NOXXON is planning to develop NOX-E36 for the 
treatment of inflammatory kidney diseases including diabetic 
nephropathy. Diabetic nephropathy is a growing public health threat 
due to the high and continually growing incidence of type II 
diabetes. Approximately thirty percent of patients diagnosed with 
diabetes develop nephropathy; twenty percent of these patients suffer
from end stage renal disease. Diabetic nephropathy is the leading 
cause for chronic kideny disease and dialysis treatment in the 
Western world.
About NOXXON Pharma AG: Berlin-based NOXXON Pharma AG is a clinical 
stage biotechnology company focusing on the development of 
Spiegelmers® for the treatment of inflammatory diseases and 
hematological indications. In addition to its in-house programs 
NOXXON discovers and develops Spiegelmers® in collaboration with 
partners from the pharmaceutical industry, including Eli Lilly, 
Hoffmann La-Roche and Pfizer. Spiegelmers® (the German word "Spiegel"
means mirror) are chemical entities based on synthetic L-nucleic 
acids. They are highly selective for their pharmacological target and
potent inhibitors of target function. The substance class exhibits 
exceptional metabolic stability and an outstanding immunogenicity 
profile - a new generation of improved therapeutics.
Contact:
Emmanuelle Delabre
NOXXON Pharma AG
Max-Dohrn-Strasse 8-10
10589 Berlin, Germany
Phone: +49 (0) 30 726247 100
FAX: +49 (0) 30 726247 225
Email:   edelabre@noxxon.com
Website: www.noxxon.com
About DEWB Deutsche Effecten- und Wechsel- Beteiligungsgesellschaft 
AG (DEWB AG, Prime Standard, Securities No.: 804100 / ISIN: 
DE0008041005) is an investment company that specialises in young and 
established medium-sized companies. The focus of our investments is 
on strong growth companies from the areas of photonics and sensor 
systems for which we provide support through shareholders' equity, 
expertise in corporate development and our sector network. Our 
regional focus lies in the German speaking countries (D, A, CH). 
Since 1997 we have invested more than 355 million Euros in 55 
companies and realized more than 420 million Euros through 36 exits, 
eight of which were in the form of IPOs. The company is located in 
Jena, one of the most successful technology and science regions in 
Germany, with a long tradition in the field of optical technologies 
and one of the most important European centres for photonics.
Contact:
Marco Scheidler
DEWB AG
Leutragraben 1
Germany, 07743 Jena
Tel: +49 (0) 3641 573 3600
Fax: +49 (0) 3641 573 3610
E-Mail:  ir@dewb-vc.com
www.dewb-vc.com
end of announcement                               euro adhoc

Further inquiry note:

Marco Scheidler
Tel.: +49 (0) 3641 573-3600
E-Mail: marco.scheidler@dewb-vc.com

Branche: Financial & Business Services
ISIN: DE0008041005
WKN: 804100
Index: CDAX, Classic All Share, Prime All Share
Börsen: Frankfurt / regulated dealing/prime standard
Berlin / free trade
Stuttgart / free trade
München / free trade

Weitere Storys: Deutsche Effecten- und Wechsel-Beteiligungsges. AG
Weitere Storys: Deutsche Effecten- und Wechsel-Beteiligungsges. AG